Heterogeneity in Preclinical Alzheimer’s Disease Trial Cohort Identified by Image-based Data-Driven Disease Progression Modelling

IMPORTANCE: Undetected biological heterogeneity adversely impacts trials in Alzheimer’s disease because rate of cognitive decline — and perhaps response to treatment — differs in subgroups. Recent results show that data-driven approaches can unravel the heterogeneity of Alzheimer’s disease progressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shand, Cameron, Markiewicz, Pawel J., Cash, David M., Alexander, Daniel C., Donohue, Michael C., Barkhof, Frederik, Oxtoby, Neil P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934776/
https://www.ncbi.nlm.nih.gov/pubmed/36798314
http://dx.doi.org/10.1101/2023.02.07.23285572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934776/
https://www.ncbi.nlm.nih.gov/pubmed/36798314
http://dx.doi.org/10.1101/2023.02.07.23285572

Ejemplares similares